In colorectal, breast, and ovary cancers, PD-L1 expression represents a better outcome (Darb-Esfahani et al., 2016; Li et al., 2016; Kitano et al., 2017), whereas worse prognostic outcomes were observed in gastrointestinal, esophageal, and pancreatic cancers as well as glioma and hepatocellular carcinoma (Ohaegbulam et al., 2015; Wang et al., 2016; Liu et al., 2017). Here, CD274 is linked to central nervous system cancer.